CIT said it arranged a $110 million senior secured credit facility for Levine Leichtman Capital Partners’ acquisition of Genova Diagnostics, a specialty clinical laboratory that has pioneered a unique systems-based approach to testing that supports the personalized treatment and prevention of chronic disease. Levine Leichtman Capital Partners is a private equity firm that makes structured investments in middle-market companies.
CIT Corporate Finance served as joint lead arranger, joint bookrunner and syndication agent for the transaction. Financing was provided by CIT Bank. Terms of the transaction were not disclosed.
“This financing provided CIT an opportunity to demonstrate our commitment to providing comprehensive financial solutions to private equity firms as they complete acquisitions,” said Eric Toizer, managing director of CIT Sponsor Finance. “As our second deal in as many years, we’re pleased to expand our relationship with Levine Leichtman Capital Partners.”
“Genova brings a highly differentiated offering to the clinical lab market that taps into the growing market of treating individuals with chronic conditions,” said Myles Kassin, director in CIT Corporate Finance, Healthcare. “We look forward to supporting the continued growth of the business.”
Lauren Leichtman, CEO and co-founder of Levine Leichtman, said, “Genova is the second investment in Levine Leichtman Capital Partners V, L.P., a $1.6 billion fund. Our growing relationship with CIT facilitated the efficient closing of this transaction, as the company’s depth of experience in the middle market, as well as its familiarity with our firm’s strategic approach to investments, combined to make CIT a logical partner.”